Range Low Price High Price Comment
30 days $26.83 $32.40 Wednesday, 1st May 2024 IMVT stock ended at $28.52. This is 3.94% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 7.18% from a day low at $27.30 to a day high of $29.26.
90 days $26.83 $39.55
52 weeks $17.53 $45.58

Historical Immunovant, Inc. prices

Date Open High Low Close Volume
May 01, 2024 $27.31 $29.26 $27.30 $28.52 1 284 847
Apr 30, 2024 $27.17 $28.55 $26.83 $27.44 1 152 141
Apr 29, 2024 $27.32 $27.81 $26.94 $27.49 1 525 624
Apr 26, 2024 $27.80 $27.97 $26.97 $27.17 1 397 016
Apr 25, 2024 $28.21 $28.52 $27.44 $27.75 1 244 152
Apr 24, 2024 $28.72 $29.54 $28.40 $28.80 652 467
Apr 23, 2024 $28.94 $29.86 $28.54 $28.61 1 032 598
Apr 22, 2024 $28.59 $28.89 $27.94 $28.74 797 600
Apr 19, 2024 $28.27 $28.64 $27.33 $28.22 1 057 034
Apr 18, 2024 $28.21 $29.22 $27.99 $28.32 1 191 375
Apr 17, 2024 $30.20 $30.35 $28.23 $28.43 1 804 454
Apr 16, 2024 $30.34 $30.96 $29.72 $30.40 938 868
Apr 15, 2024 $29.51 $30.61 $29.28 $30.47 1 188 181
Apr 12, 2024 $30.50 $30.52 $28.79 $29.35 1 464 296
Apr 11, 2024 $30.72 $31.19 $29.82 $30.72 795 216
Apr 10, 2024 $31.00 $31.16 $30.39 $30.88 759 730
Apr 09, 2024 $30.91 $31.51 $30.61 $31.17 668 222
Apr 08, 2024 $31.08 $31.38 $30.00 $30.52 1 039 579
Apr 05, 2024 $30.75 $32.40 $30.09 $31.48 1 013 047
Apr 04, 2024 $31.37 $31.70 $30.79 $30.84 1 075 573
Apr 03, 2024 $30.42 $31.25 $29.92 $31.18 1 002 540
Apr 02, 2024 $30.89 $32.12 $30.49 $30.78 871 402
Apr 01, 2024 $31.91 $32.27 $31.41 $31.61 901 890
Mar 28, 2024 $32.84 $32.95 $31.55 $32.31 1 182 495
Mar 27, 2024 $31.56 $33.13 $31.28 $32.52 907 370
Click to get the best stock tips daily for free!

About Immunovant, Inc.

Immunovant. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for... IMVT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT